Dr. Daud Discusses the Current Status of Immunotherapy in Melanoma

Partner | Cancer Centers | <b>UCSF Helen Diller Family Comprehensive Cancer Center</b>

Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Immunotherapy is at a very exciting point in melanoma, says Daud. Specifically, there were a number of combinations presented at the 2017 ASCO Annual Meeting for the relapse/refractory population that showed responses.